• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form S-3/A filed by electroCore Inc.

    1/31/25 4:22:21 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ECOR alert in real time by email
    S-3/A 1 e664166_s3a-electrocore.htm

     

    As filed with the U.S. Securities and Exchange Commission on January 31, 2025

     

    Registration No. 333-284477 

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    ___________________________

     

    PRE-EFFECTIVE AMENDMENT NO. 1

    TO

    FORM S-3
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

    ________________________

     

    ELECTROCORE, INC.
    (Exact Name of Registrant as Specified in its Charter)
    _____________________________

     

    Delaware 20-3454976
    (State or Other Jurisdiction of
    Incorporation)
    (I.R.S. Employer
    Identification Number)

     

    200 Forge Way, Suite 205

    Rockaway, New Jersey 07866
    (973) 290-0097
    (Address, Including Zip Code and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)
    __________________________

     

    Daniel S. Goldberger, Chief Executive Officer
    electroCore, Inc.
    200 Forge Way, Suite 205
    Rockaway, New Jersey 07866
    (973) 290-0097
    (Name, address, including zip code, and telephone number, including area code, of agent for service)
    _________________________

     

    Copies to:

    Ira L. Kotel, Esq.
    Dentons US LLP
    1221 Avenue of the Americas
    New York, New York 10020
    (212) 768-6700
    _________________________

     

    Approximate date of commencement of proposed sale to public: From time to time or at one time after this registration statement becomes effective in light of market conditions and other factors.

     

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.☒

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

     

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☐    

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

      

    II-1

     

     

    Explanatory Note

     

    This Pre-Effective Amendment No. 1 to the Registration Statement on Form S-3 (File No. 333-284477) (the "Registration Statement") is being filed solely for the purpose of including the delaying amendment language set forth on the cover page hereto. This Pre-Effective Amendment No. 1 does not modify any provisions of the prospectuses that form a part of the Registration Statement and, accordingly, such prospectuses have not been included herein. This Pre-Effective Amendment No. 1 is not intended to amend or delete any part of the Registration Statement except as specifically noted herein. 

     

    II-2

     

     

    PART II

     

    INFORMATION NOT REQUIRED IN PROSPECTUS

     

    Item 14. Other Expenses of Issuance and Distribution

     

    The following table sets forth all expenses, other than the underwriting discounts and commissions, payable by the registrant in connection with the sale of the securities being registered. All of such fees expenses, except for the registration fee, are estimates:

     

      Amount  
    SEC Registration fee $ 8,243.17(1)  
    FINRA Fee $ *  
    Printing Expenses $ *  
    Accounting fees and expenses $ *  
    Legal fees and expenses $ *  
    Transfer agent fees and expenses $ *  
    Trustee fees and expenses $ *  
    Warrant agent fees and expenses $ *  
    Miscellaneous fees and expenses $ *  
    Total $ *  

     

    *The calculation of these fees and expenses is dependent on the number of issuances and amount of securities offered and, accordingly, cannot be estimated at this time.

     

    1 The $100,000,000 of securities registered pursuant to this registration statement includes $46,248,961 of securities (the “Unsold Securities”) registered pursuant to the Registration Statement on Form S-3 (File No. 333-262223), originally filed on January 18, 2022, and declared effective on January 25, 2022. Pursuant to Rule 415(a)(6) under the Securities Act of 1933, as amended, the filing fees previously paid in connection with the Unsold Securities will continue to be applied to the Unsold Securities

     

    The Company shall bear all expenses in connection with the issuance and distribution of the securities being offered hereby.

     

    Item 15. Indemnification of Directors and Officers

     

    As permitted by Section 102 of the Delaware General Corporation Law, our certificate of incorporation and bylaws contain provisions that limit or eliminate the personal liability of our directors for a breach of their fiduciary duty of care as directors. The duty of care generally requires that, when acting on behalf of the corporation, directors exercise an informed business judgment based on all material information reasonably available to them. Consequently, a director will not be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for:

     

    ·any breach of the director’s duty of loyalty to us or our stockholders;

     

    ·any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

     

    ·any act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends; or

     

    ·any transaction from which the director derived an improper personal benefit.

     

    These limitations of liability do not affect the availability of equitable remedies such as injunctive relief or rescission. Our certificate of incorporation also authorizes us to indemnify our officers, directors and other agents to the fullest extent permitted under Delaware law.

     

    II-3

     

     

    As permitted by Section 145 of the Delaware General Corporation Law, our bylaws provide that:

     

    ·we may indemnify our directors, officers, and employees to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions;

     

    ·we may advance expenses to our directors, officers and employees in connection with a legal proceeding to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions; and

     

    ·we may advance expenses to our directors, officers and employees in connection with a legal proceeding to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions; and

     

    ·the rights provided in our bylaws are not exclusive.

     

    Our certificate of incorporation and our bylaws provide for the indemnification provisions described above and elsewhere herein. We have entered into separate indemnification agreements with our directors and officers which are broader than the specific indemnification provisions contained in the Delaware General Corporation Law. These indemnification agreements generally require us, among other things, to indemnify our officers and directors against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct. These indemnification agreements also generally require us to advance any expenses incurred by the directors or officers as a result of any proceeding against them as to which they could be indemnified. In addition, we have purchased a policy of directors’ and officers’ liability insurance that insures our directors and officers against the cost of defense, settlement or payment of a judgment in some circumstances. These indemnification provisions and the indemnification agreements may be sufficiently broad to permit indemnification of our officers and directors for liabilities, including reimbursement of expenses incurred, arising under the Securities Act of 1933, as amended, or the Securities Act.

     

    Insofar as indemnification for liabilities arising under the Act, may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.

     

    II-4

     

      

    Item 16. Exhibits

     

    Exhibit
    No.
    Description   Method of Filing
           
    1.1 Form of Underwriting Agreement   To be filed by amendment or pursuant to a report to be filed pursuant to Section 13 or 15(d) of the Exchange Act, if applicable, and incorporated herein by reference
           
    3.1 Certificate of Incorporation of the Registrant   Incorporated by reference to the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2018 as filed with the Commission on August 14, 2018
           
    3.2 Amended and Restated Bylaws of the Registrant   Incorporated by reference to the Company’s Current Report on Form 8-K as filed with the Commission on December 9, 2021
           
    3.3 Certificate of Designation of the Series A Preferred Stock of the Company   Incorporated by reference to the Company’s Current Report on Form 8-K as filed with the Commission on December 7, 2022
           
    3.4 Certificate of Elimination of the Series A Preferred Stock of the Company   Incorporated by reference to the Company’s Annual Report on Form 10-K for the period ended December 31, 2022 as filed with the Commission on March 8, 2023
           
    3.5 Certificate of Amendment to the Certificate of Incorporation   Incorporated by reference to the Company’s Current Report on Form 8-K as filed with the Commission on February 14, 2023
           
    4.2 Certificate of Designations for Preferred Stock   To be filed by amendment or pursuant to a report to be filed pursuant to Section 13 or 15(d) of the Exchange Act, if applicable, and incorporated herein by reference
           
    4.4 Form of Unit Agreement, including Form of Unit, if any   To be filed by amendment or pursuant to a report to be filed pursuant to Section 13 or 15(d) of the Exchange Act, if applicable, and incorporated herein by reference
           
    4.5 Form of Rights Agreement and Right Certificate, if any   To be filed by amendment or pursuant to a report to be filed pursuant to Section 13 or 15(d) of the Exchange Act, if applicable, and incorporated herein by reference
           
    4.6 Form of Senior Indenture   Previously filed

     

    II-5

     

     

    4.7 Form of Subordinated Indenture   Previously filed
           
    4.8 Form of Senior Debt Security   To be filed, if necessary, by a Current Report on Form 8-K or by amendment
           
    4.9 Form of Subordinated Debt Security   To be filed, if necessary, by a Current Report on Form 8-K or by amendment
           
    4.10 Form of Warrant Agreement, including Form of Warrant Certificate   To be filed, if necessary, by a Current Report on Form 8-K or by amendment
           
    5.1 Opinion of Dentons US LLP   Previously filed
           
    12.1 Statement regarding computation of ratios of earnings to fixed charges   To be filed by amendment or pursuant to a report to be filed pursuant to Section 13 or 15(d) of the Exchange Act, if applicable, and incorporated herein by reference
           
    23.2 Consent of Marcum LLP   Previously filed
           
    23.3 Consent of Dentons US LLP   Previously filed
           
    24.1 Power of Attorney   Previously filed
           
    25.1 Form T-1 Statement of Eligibility of Trustee   To be filed as an exhibit to a Current Report on Form 8-K or pursuant to Section 305(b)(2) of the Trust Indenture Act of 1939 under the electronic form type “305(b)(2)” and incorporated herein by reference pursuant to the requirements of Item 601(b)(2) of Regulation S-K under the Exchange Act.
           
    107 Filing Fee Table   Previously filed

     

    Item 17. Undertakings

     

    (a)The undersigned registrant hereby undertakes:

     

    (1)  To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i)To include any prospectus required by section 10(a)(3) of the Securities Act;

     

    (ii)  To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;

     

    (iii)  To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

     

    II-6

     

     

    provided, however, that paragraphs (1)(i), (1)(ii) and (1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

     

    (2)  That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3)  To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (4)  That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

     

    (i)  Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

     

    (ii)  Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

     

    (iii)  The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

     

    (iv)  Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

     

    (b)   The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Exchange) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c)  The undersigned registrant hereby undertakes to supplement the prospectus, after the expiration of the subscription period, to set forth the results of the subscription offer, the transactions by the underwriters during the subscription period, the amount of unsubscribed securities to be purchased by the underwriters, and the terms of any subsequent reoffering thereof. If any public offering by the underwriters is to be made on terms differing from those set forth on the cover page of the prospectus, a post-effective amendment will be filed to set forth the terms of such offering.

     

    (d)  The undersigned registrant hereby undertakes that:

     

    (1)  For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

     

    II-7

     

     

    (2)  For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3)  For the purpose of determining liability under the Securities Act to any purchaser if the registrant is relying on Rule 430B: (A) each prospectus filed pursuant to Rule 424(b)(3) shall be deemed to be part of this registration statement as of the date the filed prospectus was deemed part of and included in this registration statement; and (B) each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of this registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act shall be deemed to be part of and included in this registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the registrant and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.

     

    (e)  Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    (f)  The undersigned registrant hereby undertakes to file an application for the purpose of determining the eligibility of the trustee to act under subsection (a) of section 310 of the Trust Indenture Act in accordance with the rules and regulations prescribed by the Commission under section 305(b)(2) of the Act.

     

    II-8

     

     

    SIGNATURES

     

    Pursuant to the requirement of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Pre-Effective Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Rockaway, State of New Jersey, on this 31st day of January 2025.

     

    ELECTROCORE, INC.  
       
    By: /s/ Joshua S. Lev  
      Joshua S. Lev  
      Chief Financial Officer  

     

    Pursuant to the requirements of the Securities Act of 1933, this Pre-Effective Amendment No. 1 to the Registration Statement has been signed by the following persons in the capacities and on the date indicated below.

     

    Signature   Capacity   Date
             
    *        
    Daniel S. Goldberger   Chief Executive Officer and Director (Principal Executive Officer)   January 31, 2025
             
    /s/ Joshua S. Lev        
    Joshua S. Lev   Chief Financial Officer (Principal Financial and Accounting Officer)   January 31, 2025
             
    *        
    F. Peter Cuneo   Chairman of the Board   January 31, 2025
             
    *        
    Thomas J. Errico, M.D.   Director   January 31, 2025
             
    *        
    John P. Gandolfo   Director   January 31, 2025
             
    *        
    Julie A. Goldstein   Director   January 31, 2025
             
    *        
    Thomas M. Patton   Director   January 31, 2025
             
    *        
    Charles S. Theofilos, M.D.   Director   January 31, 2025
             
    *        
    Patricia Wilber   Director   January 31, 2025

      

    *By: /s/ Joshua S. Lev  
    Joshua S. Lev  
    Attorney-in-fact  

     

    II-9

    Get the next $ECOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ECOR

    DatePrice TargetRatingAnalyst
    1/19/2022$3.00 → $2.75Buy
    HC Wainwright & Co.
    7/27/2021$3.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $ECOR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TAC-STIM Demonstrates Significant Performance Improvements in Active-Duty United States Air Force Airmen

    ROCKAWAY, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced the publication of a peer reviewed paper titled "Non-Invasive Transcutaneous Vagal Nerve Stimulation Enhances Mood, Task Performance, and Learning in a High-Stress Military Training Environment" which will be presented at the Applied Human Factors and Ergonomics (AHFE2025) Conference on December 8, 2025. The paper presents results from the latest controlled study involving the Company's proprietary TAC-STIM™ non-invasive transcutaneous vagal nerve stimulation (tVNS) device, which confirm the ability of the TAC-STIM device t

    12/2/25 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

    ROCKAWAY, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. The conference will take place in New York on Thursday, November 20, 2025 at The Westin NY Grand Central Hotel. Management will host one-on-one meetings throughout the day. Investors who wish to request a meeting should contact their sales representative at Canaccord Genuity or reach out to electroCore Investor Relations at [email protected]. About electroCore, Inc. electroCore, Inc. is a bioelectronic technology c

    11/10/25 4:05:00 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore Announces Third Quarter 2025 Financial Results

    Net sales of $8.7 million increased 33% vs. Q3 2024; YTD net sales of $22.8 million increased 26% vs. first nine months of 2024 Cash, cash equivalents, restricted cash, and marketable securities ("Total Cash") of $13.2 million as of September 30, 2025  Company to host a conference call and webcast today, November 5, 2025, at 4:30 p.m. EDT ROCKAWAY, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced financial results for the three and nine months ended September 30, 2025. Recent Highlights Record revenue for Q3 2025 of $8.7 million, a 33% increase over Q3'2024Year-to-date revenue

    11/5/25 4:05:00 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by electroCore Inc.

    SCHEDULE 13G/A - electroCore, Inc. (0001560258) (Subject)

    11/13/25 2:27:02 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by electroCore Inc.

    10-Q - electroCore, Inc. (0001560258) (Filer)

    11/5/25 4:26:07 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - electroCore, Inc. (0001560258) (Filer)

    11/5/25 4:16:00 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Lev Joshua S. sold $12,625 worth of shares (2,500 units at $5.05), decreasing direct ownership by 10% to 21,667 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    12/5/25 4:15:45 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Executive Officer Goldberger Daniel S bought $4,840 worth of shares (1,000 units at $4.84), increasing direct ownership by 0.34% to 292,565 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    12/3/25 7:00:20 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Lev Joshua S. sold $13,386 worth of shares (2,166 units at $6.18), decreasing direct ownership by 8% to 23,667 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    11/14/25 4:33:41 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on electroCore with a new price target

    HC Wainwright & Co. reiterated coverage of electroCore with a rating of Buy and set a new price target of $2.75 from $3.00 previously

    1/19/22 6:31:24 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ladenburg Thalmann initiated coverage on electroCore with a new price target

    Ladenburg Thalmann initiated coverage of electroCore with a rating of Buy and set a new price target of $3.00

    7/27/21 7:13:01 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Maxim Group resumed coverage on electroCore with a new price target

    Maxim Group resumed coverage of electroCore with a rating of Buy and set a new price target of $3.00

    3/13/21 8:17:18 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Goldberger Daniel S bought $4,840 worth of shares (1,000 units at $4.84), increasing direct ownership by 0.34% to 292,565 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    12/3/25 7:00:20 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Errico Thomas J. bought $67,050 worth of shares (15,000 units at $4.47), increasing direct ownership by 6% to 281,401 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    8/13/25 6:05:11 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Executive Officer Goldberger Daniel S bought $4,230 worth of shares (1,000 units at $4.23), increasing direct ownership by 0.34% to 291,565 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    8/12/25 6:05:12 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    Leadership Updates

    Live Leadership Updates

    View All

    electroCore Appoints Elena Bonfiglioli to Board of Directors

    ROCKAWAY, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Elena Bonfiglioli, an accomplished healthcare executive, has been appointed to electroCore's Board of Directors, effective September 2, 2025. Ms. Bonfiglioli's appointment follows the retirement from the Board of Peter Cuneo. Ms. Bonfiglioli has been working in the health sector for more than two decades. She currently serves as Microsoft's Global Business Leader for Healthcare, Pharma Life Sciences, and the International clinical applications' solutions, responsible for go-to-market, commercial, and partnerships, enabling

    9/3/25 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore Appoints James C. Theofilos to the Board of Directors

    ROCKAWAY, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that James C. Theofilos has been appointed to the Board of Directors, effective August 1, 2025. "I'm honored to have been appointed to the Board of Directors at electroCore," said Mr. Theofilos. "For nearly two decades, the Theofilos family has deeply believed in the power of the vagus nerve and proudly supported electroCore as both an early investor and founding partner. At Microsoft, I've had the privilege of serving as the global finance lead for our healthcare and life sciences business — working alongside some of the worl

    8/5/25 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore to Join Russell Microcap® Index

    ROCKAWAY, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its stock is on the preliminary additions list for inclusion in the Russell Microcap® Index after its 2024 annual reconstitution. The newly reconstituted indexes will take effect after the market close on June 28, 2024, with the newly effective reconstituted family of indices beginning trading after the open of trading on July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on May 24, 2024. "We are pleased to have been selected to join the Russell Microcap® Index," said Brian Posner, Chief Finan

    6/11/24 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    Financials

    Live finance-specific insights

    View All

    electroCore Announces Third Quarter 2025 Financial Results

    Net sales of $8.7 million increased 33% vs. Q3 2024; YTD net sales of $22.8 million increased 26% vs. first nine months of 2024 Cash, cash equivalents, restricted cash, and marketable securities ("Total Cash") of $13.2 million as of September 30, 2025  Company to host a conference call and webcast today, November 5, 2025, at 4:30 p.m. EDT ROCKAWAY, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced financial results for the three and nine months ended September 30, 2025. Recent Highlights Record revenue for Q3 2025 of $8.7 million, a 33% increase over Q3'2024Year-to-date revenue

    11/5/25 4:05:00 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore Announces Second Quarter 2025 Financial Results

    Net sales of $7.4 million increased 20% vs. Q2'2024; YTD net sales of $14.1 million increased 22% vs. first half of 2024 Cash, cash equivalents, restricted cash, and marketable securities of $7.4 million as of June 30, 2025  Company to host a conference call and webcast today, August 6, 2025, at 4:30 p.m. EDT ROCKAWAY, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a commercial-stage bioelectronic technology company, today announced financial results for the three and six months ended June 30, 2025. Recent Highlights Record revenue for Q2'2025 of $7.4 million, a 20% increase over Q2'2024Year-to-Date revenue of $14.1 million, a

    8/6/25 4:05:00 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore Announces First Quarter 2025 Financial Results

    First quarter 2025 net sales of $6.7 million, an increase of 23% over first quarter 2024 Closed the acquisition of NeuroMetrix, Inc. ("NeuroMetrix"); first quarter 2025 unaudited Quell net sales of approximately $170,000  Company to host a conference call and webcast today, May 7, 2025 at 4:30 PM EDT ROCKAWAY, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a commercial-stage bioelectronic technology company, today announced financial results for the first quarter ended March 31, 2025. Recent Highlights Reported first quarter 2025 revenue of $6.7 million, a 23% increase over first quarter 2024Revenue excluding TAC-STIM totaled $

    5/7/25 4:05:00 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Stock Movement: Insider Purchase at electroCore Inc. on Jun 6

    **Analysis of Recent Insider Purchase at electroCore Inc.** An insider purchase was recently made at electroCore Inc. by Goldberger Daniel S on June 6, 2024. This transaction involved the purchase of $247,587 worth of shares, equating to 38,505 units at an average price of $6.43 per share. As a result of this purchase, Goldberger's direct ownership in the company increased by 18% to 249,565 units, as reported in the SEC Form 4 filing. Looking at the historical insider transactions at electroCore Inc., several interesting patterns emerge when analyzing the timing, price, volume, purchaser's role, and more. On August 8, 2023, Goldstein Julie Ann and Cuneo F Peter both filed SEC Form 4 report

    6/10/24 12:57:57 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by electroCore Inc. (Amendment)

    SC 13D/A - electroCore, Inc. (0001560258) (Subject)

    6/7/24 4:33:08 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by electroCore Inc. (Amendment)

    SC 13G/A - electroCore, Inc. (0001560258) (Subject)

    2/14/24 3:15:55 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13D filed by electroCore Inc.

    SC 13D - electroCore, Inc. (0001560258) (Subject)

    12/18/23 4:10:26 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care